KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Tax Provisions: 2015-2024

Historic Tax Provisions for Acadia Pharmaceuticals (ACAD) over the last 10 years, with Dec 2024 value amounting to $31.6 million.

  • Acadia Pharmaceuticals' Tax Provisions fell 550.26% to -$27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year increase of 51.25%. This contributed to the annual value of $31.6 million for FY2024, which is 207.03% up from last year.
  • According to the latest figures from FY2024, Acadia Pharmaceuticals' Tax Provisions is $31.6 million, which was up 207.03% from $10.3 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Tax Provisions ranged from a high of $31.6 million in FY2024 and a low of $351,000 during FY2021.
  • Moreover, its 3-year median value for Tax Provisions was $10.3 million (2023), whereas its average is $14.8 million.
  • In the last 5 years, Acadia Pharmaceuticals' Tax Provisions tumbled by 42.55% in 2021 and then skyrocketed by 621.08% in 2022.
  • Acadia Pharmaceuticals' Tax Provisions (Yearly) stood at $611,000 in 2020, then tumbled by 42.55% to $351,000 in 2021, then soared by 621.08% to $2.5 million in 2022, then spiked by 306.95% to $10.3 million in 2023, then spiked by 207.03% to $31.6 million in 2024.